Economic Value Study Results Based on PARTNER IIa and SAPIEN 3i Trials
During TCT 2017 Congress in Denver, Dr. David J. Cohen from Saint-Luke’s Mid America Heart Institute presented the outcomes of a cost-effectiveness assessment of TAVI vs SAVR based on PARTNER IIa/SAPIEN 3i studies:
What Do These Results Mean from a Provider Perspective?
- TAVI with SAPIEN 3 valve improves all-cause mortality and disabling stroke rates
- TAVI with SAPIEN 3 valve supports hospital value through reduced procedure time and length of stay
Cohen D. et al. 2017. PARTNER IIA and SAPIEN 3 Cost-effectiveness: Cost-effectiveness of TAVR vs SAVR in Intermediate-Risk Patients With Aortic Stenosis. Presented at TCT 2017
What's included?
- You will be able to discover the study design and methodology
- Get latest updates on survival, procedural time and hospital stay differences
- Find out about in-hospital and follow-up costs of TAVI vs SAVR
